Evidence map›Paper›PMID 42469833›Full record

ArticleCell communication and signaling : CCS2026

SPP1-positive macrophages drive trastuzumab resistance in HER2-positive breast cancer.

Donghui Wang, Guodong Li, Yajie Lu, Ruoxin Du, Xiangmei He, Jiahui Sun, Danxi Li, Siyuan Wang, Yimin Liu, Shuning Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Donghui Wang *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an, People's Republic of China.
Guodong Li *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an, People's Republic of China.
Yajie Lu *Department of Clinical Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, People's Republic of China.
Ruoxin DuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an, People's Republic of China.
Xiangmei HeDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, People's Republic of China.
Jiahui Sun988 Hospital of Joint Logistic Support Force, Zheng Zhou, People's Republic of China.
Danxi LiDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, People's Republic of China.
Siyuan WangDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, People's Republic of China.
Yimin LiuSchool of Basic Medicine, Air Force Medical University, Xi'an, People's Republic of China.
Shuning WangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an, People's Republic of China.
Lan HouDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, People's Republic of China.
Juliang ZhangDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, People's Republic of China. vascularzhang@163.com.
Yuan GaoState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an, People's Republic of China. gaoyuan321@fmmu.edu.cn.
Cun ZhangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an, People's Republic of China. zhangcun@fmmu.edu.cn.

Funding

National Natural Science Foundation of China 82072910, 81902678, 82373894, 82304540, and 82172788Shaanxi Science Fund for Distinguished Young Scholars No. 2022JC-53the Joint Innovation Fund of Xijing Hospital Innovation Research Institute LHJJ2023-YX06
6 · The paper itself

Abstract

Trastuzumab-based HER2-targeted therapy remains the cornerstone treatment for HER2-positive breast cancer. However, its clinical efficacy is significantly modulated by the tumor microenvironment (TME). Our single-cell sequencing analysis of clinical samples revealed that patients with poor radiologic response after trastuzumab-based neoadjuvant therapy presented significant enrichment of TIGIT

Indexed as

Breast NeoplasmsDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesMacrophagesTrastuzumabAnimalsCell Line, TumorFemaleHumansKiller Cells, NaturalMiceTumor MicroenvironmentERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabHER2-positive breast cancerSingle-cell RNA sequencingTrastuzumabTumor microenvironment

Identifiers

PMID42469833
PMCPMC13663260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.